SEC Tracker
Get the app

Hemab Therapeutics Holdings COAG

Hemab Therapeutics reports Q3 2026 results and trial updates

Hemab Therapeutics Holdings (COAG) filed an 8-K with the SEC on Nov 10, 2026, 7:08 am ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Initiated SOLARA, a pivotal Phase 3 trial for sutacimig in Glanzmann thrombasthenia
  2. Dosed first participant in Phase 1 trial of HMB-003 for heavy menstrual bleeding
  3. Announced data showing HMB-003 reduced severe menstrual bleeding in a monkey model
  4. Appointed Keli Walbert to Board of Directors with commercial leadership experience

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Hemab Therapeutics Holdings files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.